Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer
Dose-escalation Phase:
Eligible patients will receive FF-10832 in 28 day or 21 day cycles. Dosing will continue until progression of disease, observation of unacceptable adverse events, intercurrent illness, or changes in the patient's condition that prevents further study participation after discussion between the Investigator and the Medical Monitor. A number of cohorts will be enrolled sufficient to determine the MTD and to identify the RP2D.
Expansion Phase:
One cohort of biliary tract cancer will enroll up to 18 patients in a 21 day cycle.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: Treatment at 1.2 mg/m2 | Experimental | FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle |
|
| Cohort 2: Treatment at 2.4 mg/m2 | Experimental | FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle |
|
| Cohort 3: Treatment at 4.8 mg/m2 | Experimental | FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle |
|
| Cohort 4: Treatment at 8 mg/m2 | Experimental | FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle |
|
| Expansion Cohort: Treatment at Recommended Phase 2 Dose (RP2D) | Experimental | For patients with biliary tract cancer: FF-10832 Gemcitabine Liposome Injection, RP2D administered intravenously (IV) on Day 1 of each 21-day cycle |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FF-10832 Gemcitabine Liposome Injection | Drug | FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determine incidence of Treatment Emergent Adverse Events (TEAE) | Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs) | 2.5 years |
| Identify dose-limiting toxicities (DLT) of FF-10832 | DLT is defined as any adverse event at least possibly related to FF-10832, and meeting specified DLT criteria | 2.5 years |
| Determine maximun tolerated dose (MTD) of FF-10832 | MTD is defined as the next lower dose of a cohort where patients experienced a DLT | 2.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Disease Assessment by CT or MRI scan for solid tumors | Disease assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1), clinical benefit is defined as best response of complete response (CR), partial response (PR), stable disease (SD) or disease progression (DP) | 2.5 years |
| Disease Assessment by CT or MRI + PET scan for pancreatic cancer |
Not provided
Inclusion Criteria:
Males and females ≥ 18 years of age
Histologically or cytologically confirmed metastatic solid tumor, relapsed or refractory to standard therapy, or for which no standard therapy is available that is expected to improve survival by at least three months
At least 3 weeks beyond the last chemotherapy (or 3 half-lives, whichever is shorter), radiotherapy, major surgery, or experimental treatment, and recovered from all acute toxicities (≤ Grade 1), prior to the first dose of FF-10832
Cohort expansion phase: (biliary tract cancer):
Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 1
Life expectancy of ≥ 3 months
Ability to provide written informed consent
Exclusion Criteria:
7. Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment
8. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
9. Pregnant or breast-feeding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Honor Health Research Institute | Scottsdale | Arizona | 85258 | United States | ||
| University of Arizona Cancer Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Open label, dose escalation
Not provided
Not provided
None, open label
Not provided
|
|
For solid tumors assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1), clinical benefit is defined as best response of complete response (CR), partial response (PR), stable disease (SD) or disease progression (DP). European Organisation for Research and Treatment of Cancer (EORTC) criteria will be utilized for PET response assessments. |
| 2.5 years |
| Duration of Response | Duration of Response is calculated from the date of first response to the date of progression or death | 2.5 years |
| Duration of Stable Disease | Duration of Stable Disease is the length of time from the start of the treatment until the criteria for progression are met | 2.5 years |
| Time to progression (TTP) | Time to progression is calculated from the date of first treatment to the date of first progression | 2.5 years |
| Progression-free survival (PFS) | Progression-free survival will be calculated from the date of first treatment to the date of progression or death | 2.5 years |
| Overall survival (OS) | Overall survival will be calculated from the date of first treatment to the date of death from any cause; patients who do not experience death will be censored at the last follow-up time. | 2.5 years |
| Tucson |
| Arizona |
| 85719 |
| United States |
| Hoag Memorial Hospital Comprehensive Cancer Center | Newport Beach | California | 92658 | United States |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | United States |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States |
| MD Anderson Cancer Research Center | Houston | Texas | 77030 | United States |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | United States |
| ID | Term |
|---|---|
| D001661 | Biliary Tract Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided